Editorial team
Who writes and reviews GLP-1 Nutrition
Every clinical guidance article on this site is reviewed by a board-certified endocrinologist before publication. The editorial team is a small group of obesity-medicine and dietitian clinicians whose practices consist substantially of GLP-1 receptor agonist patients.
Priya Krishnan, MD, ABOM
Priya Krishnan is a board-certified obesity medicine physician (American Board of Obesity Medicine, ABOM). She founded GLP-1 Nutrition in 2024 after a year of fielding the same nutrition questions from patients newly started on semaglutide and tirzepatide: how much protein, how to keep eating when appetite drops, how to track what little you eat. The site exists because answering those questions one consult at a time was not scaling, and the existing internet content on GLP-1 nutrition was either drug-vendor marketing or generic weight-loss copy unrelated to the actual physiology of GLP-1 receptor agonist therapy.
Hannah Ekberg, MS, RD, CDCES
Hannah Ekberg is a Registered Dietitian and Certified Diabetes Care and Education Specialist whose clinical practice has shifted, over 2024 and 2025, to predominantly GLP-1 RA patients. Her clinical interest is body composition under GLP-1 therapy — specifically the protein and resistance-training inputs needed to preserve lean mass while losing fat at the rates these medications produce. She writes the per-medication nutrition guides and the protein-target series.
Marcus Adeyemi, RD
Marcus Adeyemi contributes the practical-cooking and side-effect-management content on GLP-1 Nutrition. His pieces cover what to eat through the first weeks of a dose escalation, how to adjust meals for nausea, and the meal-timing patterns that work when the typical "three meals" cadence stops feeling natural.
Jonathan Park, MD, FACE
Jonathan Park is a board-certified endocrinologist who serves as the medical reviewer for GLP-1 Nutrition. Every clinical guidance article is reviewed and signed off by him before publication. His clinical practice covers adult Type 2 diabetes and obesity medicine; his subspecialty interest is the long-term metabolic and body-composition follow-up of patients on GLP-1 receptor agonists.